AI-Informed Health App Aids Diabetes Outcomes
By Lori Solomon HealthDay Reporter
WEDNSDAY, May 15, 2024 -- Use of an artificial intelligence (AI)-informed health app aids diabetes outcomes and cuts atherosclerotic cardiovascular disease (ASCVD) risk, according to a study presented at the annual meeting of the American Association of Clinical Endocrinology, held from May 9 to 11 in New Orleans.
Paramesh Shamanna, M.D., from the Bangalore Diabetes Centre in India, and colleagues evaluated the effectiveness of the digital twin (DT) technology to improve hemoglobin A1C (HbA1c) and 10-year ASCVD risk. The analysis included 208 individuals assigned to the DT intervention (a mobile app that uses AI and Internet of Things to integrate multidimensional data to give precision nutrition and health recommendations) and 81 assigned to standard of care.
The researchers found that overall, 72.5 percent sustained diabetes remission in one year. There was a significantly larger difference in the change in HbA1c in the DT group versus standard of care (−3 versus −0.2). Further, the DT group had a marked decrease in the ASCVD risk profile at 360 days, with 76.6 percent of participants categorized as low-risk versus 49.1 percent at baseline. By comparison, the standard-care group showed a marginal increase in the low-risk category from 43.2 to 45.7 percent. In the DT group, reductions in the high-risk category were more pronounced, while the standard-care group remained unchanged. There was a significant positive correlation between the change in ASCVD risk in the DT group versus the standard-care group (−4.3 versus −0.97).
"Digital twin technology significantly enhanced HbA1c reduction and reduced 10-year ASCVD risk in type 2 diabetes mellitus patients, outperforming standard care and demonstrating its potential in precision diabetes management," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
Statins Reduce CVD Risk in Adults Aged 75 to 85 and 85 Years and Older
TUESDAY, May 28, 2024 -- For patients aged 75 years and older, statin therapy is associated with a risk reduction in cardiovascular diseases (CVDs), according to a study published...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.